Your browser is not currently configured to accept cookies from this website.
This means that the site will not run as smoothly/quickly as possible and could result in certain functionality not working as designed. Endocrine Society Statement of Principle Scientific Statements Clinical Practice Guidelines Continuing Medical Education: Clinical Practice Guidelines and Translational Endocrinology & Metabolism Position Statements Click the title above to read Wiley’s book proposal guidelines.
Therapeutic drug monitoring (TDM) may help to minimize toxicity while adequate drug exposure is maintained.
Conventional plasma sampling and monitoring might be hindered in many parts of the world by logistical problems that may be solved by dried blood spot (DBS) sampling.
The aim of this study was to develop and validate a novel method for TDM of linezolid in MDR-TB patients using DBS sampling.
Plasma, venous DBS, and capillary DBS specimens were obtained simultaneously from eight patients receiving linezolid.
An easy sampling procedure and high sample stability may facilitate TDM, even in underdeveloped countries with limited resources and where conventional plasma sampling is not feasible. The World Health Organization (WHO) classifies linezolid as a reserve antituberculosis drug for the treatment of multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB) (33).